bromfenac has been researched along with loteprednol etabonate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Holland, EJ; Lane, SS | 1 |
| Al-Awadi, A; Chan, CC; Somani, S; Tokko, HA | 1 |
2 trial(s) available for bromfenac and loteprednol etabonate
| Article | Year |
|---|---|
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anterior Chamber; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Azepines; Benzophenones; Bromobenzenes; Cataract Extraction; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Glucocorticoids; Humans; Inflammation; Intraocular Pressure; Loteprednol Etabonate; Male; Middle Aged; Ophthalmic Solutions; Postoperative Complications; Prednisolone; Topoisomerase II Inhibitors; Uveitis, Anterior; Visual Acuity | 2013 |
Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
Topics: Aged; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Cataract Extraction; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intraocular Pressure; Intraoperative Period; Loteprednol Etabonate; Male; Ophthalmic Solutions; Patient Satisfaction; Postoperative Complications; Prospective Studies; Time Factors; Treatment Outcome; Visual Acuity | 2019 |
1 other study(ies) available for bromfenac and loteprednol etabonate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |